|
|
Article: Eisai Inc. Breaks Ground for New Oncology Facility in Research Triangle Park.
- Article from:
- PR Newswire
- Article date:
- November 13, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Oncology Market Entry Leads to New Facility
RESEARCH TRIANGLE PARK, N.C., Nov. 13 /PRNewswire/ -- Eisai Inc., a Teaneck, New Jersey-based pharmaceutical company, broke ground today for a new pharmaceutical production and formulation research and development facility for parenteral -- or intravenous -- oncology treatments in Research Triangle Park (RTP), North Carolina. Eisai has a number of drugs in development for patients with cancer and recently entered the market through the acquisition of four oncology-related products from Ligand Pharmaceuticals.
Eisai will invest $90 million in the 65,000 square foot facility, which will encompass aseptic ...
Related newspaper, magazine, and journal articles:
|
|
Article: Eisai to Acquire MGI PHARMA for $41 Per Share in an All ...
Business Wire;
December 10, 2007 ;
700+ words
... ... 2006 to March 31, 2012, Eisai has continued to achieve steady ... unmet medical needs exist. Eisai has strengthened its oncology ... technology. In addition, Eisai is building a new oncology ... formulation R&D at its North Carolina site. The Transaction The ...
|
|